Meeting
2021 Genitourinary Cancers Symposium
MK-6482, a hypoxia-inducible factor 2α inhibitor (HIF-2α), versus everolimus in heavily pretreated, immune checkpoint–inhibitor-resistant, advanced clear cell renal cell carcinoma (ccRCC): Phase III study.
Authors
Toni K. Choueiri
Dana-Farber Cancer Institute, Boston, MA
Toni K. Choueiri , Laurence Albiges , Li Fan , Rodolfo F. Perini , Donna Vickery , Thomas Powles , Brian I. Rini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04195750
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr TPS368)
DOI
10.1200/JCO.2021.39.6_suppl.TPS368
Abstract #
TPS368
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase III study of the hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC).
First Author: Toni K. Choueiri
Poster
2020 Genitourinary Cancers Symposium
Phase II study of the oral hypoxia-inducible factor 2α (HIF-2 α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).
First Author: Scott S. Tykodi
Poster
2023 ASCO Annual Meeting
LITESPARK-024: Randomized phase 1/2 study of belzutifan with or without palbociclib for treatment of advanced renal cell carcinoma (RCC).
First Author: David F. McDermott
Poster
2022 ASCO Annual Meeting
LITESPARK-022: A phase 3 study of pembrolizumab + belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC).
First Author: Toni K. Choueiri